Brief: VBL Therapeutics Says Data Safety Committee Gives Clearance To Continue Phase 3 Study Of Ovarian Cancer Treatment
17/09/2021 12:08
Sept 17 (Reuters) - Vascular Biogenics Ltd VBLT.O :
* VBL THERAPEUTICS ANNOUNCES INDEPENDENT DATA SAFETY
MONITORING
COMMITTEE PROVIDES CLEARANCE TO CONTINUE OVAL PHASE 3
REGISTRATION-ENABLING STUDY OF VB-111 IN OVARIAN CANCER
* VASCULAR BIOGENICS LTD - REMAINS ON TRACK TO COMPLETE
ENROLLMENT
IN 1Q22
Source text for Eikon: ID:nGNX1PT0jt
Further company coverage: VBLT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Notable Labs
See all newsUS STOCKS-Wall St ends sharply lower following Trump's anti-Powell tirade
US STOCKS-Wall St ends sharply lower amid Trump's tirade against Fed's Powell
US STOCKS-Wall St tumbles as Trump ramps up tirade against Fed's Powell
Brief: Notable Labs Says Co, Units Filed Voluntary Petition Under Provisions Of Chapter 7 Of Title 11 Of US Bankruptcy Code
Brief: Notable Labs Approved A Streamlined Operating Plan Which Includes Exploring Strategic Alternatives